Buochs

This trial is a rollover study for adults who previously participated in specific Incyte-sponsored clinical trials involving the drug povorcitinib. It focuses on people with Hidradenitis Suppurativa HS, a condition being studied to better understand the long-term safety and effects of continuing povorcitinib treatment. The purpose is to monitor participants who have already benefited from povorcitinib in earlier studies, now entering an extended phase to further evaluate safety and treatment outcomes. Participants will continue taking povorcitinib orally, following the same dose and schedule they had in their original parent study. This study does not test new doses or compare treatments but observes continued use of the drug under the established regimen. The study may last for up to approximately three years, reflecting extended monitoring rather than initial treatment phases. During the study, participants will attend scheduled visits for assessments, including tracking any treatment-emergent adverse events and measuring symptom counts related to HS. Researchers will collect safety data over the long term and observe clinical responses. Participants must adhere to study procedures and avoid pregnancy or fathering children as required. The study aims to provide detailed safety information over an extended period while participants remain on the drug regimen from their original trial.

Researchers are studying the medical care and treatment of patients with moderate-to-severe atopic dermatitis AD, a common chronic inflammatory skin condition that significantly affects quality of life and has economic impact. This national, prospective, multicenter registry in Switzerland aims to fill the gap in detailed data on how AD is managed and to assess the safety and effectiveness of approved therapies in real-world settings. The study includes children aged 12 years and older, adolescents, and adults with moderate-to-severe AD. No experimental treatments are given as part of the study. Instead, patients are followed for at least 24 months with periodic visits to document their clinical information, treatments, patient-reported outcomes, and reasons for treatment choices. Participants will undergo standardized assessments over the observation period to record demographic data, treatment history, comorbidities, and changes in disease severity using tools like SCORAD, EASI, DLQI, POEM, and RECAP. The study primarily evaluates the types of systemic therapies used, while also monitoring quality of life and disease progression. There is no maximum follow-up duration, allowing long-term data collection.